%PDF-1.4
%
34 0 obj
<>
endobj
31 0 obj
<>
endobj
94 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-05-12T08:32:22Z
2024-03-28T06:05:44-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T06:05:44-07:00
application/pdf
Heather
2004-230.june
uuid:18241ed5-1dd2-11b2-0a00-be08271d5700
uuid:18241ed8-1dd2-11b2-0a00-bf0000000000
endstream
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
35 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 10 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
104 0 obj
[108 0 R]
endobj
105 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
[(ordinary clinical care. J Rheumatol 2004;31:1)36.8 (143-51.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (Pope JE, )54.8 (Anderson JJ, Felson DT)73.9 (. )54.8 (A)-220.1 (meta-analysis of the ef)17.7 (fects of)]TJ
1.675 -1.25 Td
[(nonsteroidal anti-inflammatory drugs on blood pressure. )54.8 (Arch)]TJ
0 -1.25 TD
(Intern Med 1993;153:477-84.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Johnson )54.8 (AG, Nguyen )17.7 (TV)128.8 (, Day RO. Do nonsteroidal anti-)]TJ
1.675 -1.25 Td
[(inflammatory drugs af)17.7 (fect blood pressure. )54.8 (A)-220.1 (meta-analysis. )54.8 (Ann)]TJ
T*
(Intern Med 1994;121:289-300.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Fujita )17.7 (T)74 (,)-0.1 ( )36.8 (Y)99.8 (amashita N, )36.8 (Y)99.8 (amashita K. Ef)17.7 (fect of indomethacin on)]TJ
1.675 -1.25 Td
(antihypertensive action of captopril in hypertensive patients. Clin)Tj
T*
(Exp Hypertens 1981;3:939-52.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Covi G, Minuz P)110.7 (, Capuzzo G, Lechi C, Delva P)110.7 (, Lechi )54.8 (A.)]TJ
1.675 -1.25 Td
[(Reduction of the antihypertensive ef)17.7 (fect of captopril induced by)]TJ
T*
(prostaglandin synthetase inhibition. Int J Clin Pharmacol Res)Tj
0 Tc 0 Tw T*
(1984;4:47-52.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Seto S, )54.8 (Aoi )17.7 (W)91.8 (, Iwami K, et al. Ef)17.7 (fect of propranolol and)]TJ
1.675 -1.25 Td
(indomethacin on the depressor action of captopril in patients with)Tj
T*
[(essential hypertension. Clin Exp Hypertens )54.8 (A)-220.1 (1987;9:623-7.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Quilley J, Duchin KL, Hudes EM, McGif)17.7 (f JC. )17.7 (The antihypertensive)]TJ
1.675 -1.25 Td
[(ef)17.7 (fect of captopril in essential hypertension: relationship to)]TJ
T*
(prostaglandins and the kallikrein-kinin system. J Hypertens)Tj
0 Tc 0 Tw T*
(1987;5:121-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Higashimori K, Gante J, Holzemann G, Inagami )17.7 (T)74 (. Significance of)]TJ
2.175 -1.25 Td
(vascular renin for local generation of angiotensins. Hypertension)Tj
0 Tc 0 Tw T*
(1991;17:270-7.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Ashida )17.7 (T)74 (, Nishioeda )36.8 (Y)128.9 (, Kimura G, et al. Ef)17.7 (fects of salt,)]TJ
2.1381 -1.25 Td
(prostaglandin, and captopril on vascular responsiveness in essential)Tj
T*
[(hypertension. )54.8 (Am J Hypertens 1989;2:640-2.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Whelton )54.8 (A, Fort JG, Puma JA, Normandin D, Bello )54.8 (AE, )17.7 (V)110.8 (erbur)17.7 (g)]TJ
2.175 -1.25 Td
[(KM. SUCCESS )17.7 (VI Study Group. Cyclooxygenase-2-specific)]TJ
33 35 Td
(inhibitors and cardiorenal function: a randomized, controlled trial)Tj
T*
(of celecoxib and rofecoxib in older hypertensive osteoarthritis)Tj
T*
[(patients. )54.8 (Am J )17.7 (Ther 2001;8:85-95. Erratum in: )54.8 (Am J )17.7 (Ther)]TJ
0 Tc 0 Tw T*
(2001;8:220.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Whelton )54.8 (A, )17.7 (White )17.7 (WB, Bello )54.8 (AE, Puma JA, Fort JG. SUCCESS-)]TJ
2.175 -1.25 Td
[(VII Investigators. Ef)17.7 (fects of celecoxib and rofecoxib on blood)]TJ
T*
(pressure and edema in patients )Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.5 (\003)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 13.746 0 Td
(65 years of age with systemic)Tj
-13.7461 -1.25 Td
[(hypertension and osteoarthritis. )54.8 (Am J Cardiol 2002;90:959-63.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (Nietert PJ, Ornstein SM, Dickerson LM, Rothenber)17.7 (g RJ.)]TJ
2.175 -1.25 Td
(Comparison of changes in blood pressure measurements and anti-)Tj
T*
[(hypertensive therapy in older)39.7 (, hypertensive, ambulatory care)]TJ
T*
(patients prescribed celecoxib or rofecoxib. Pharmacotherapy)Tj
0 Tc 0 Tw T*
(2003;23:1416-23.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Schwartz JI, )17.7 (V)110.8 (andormael K, Malice MP)110.7 (, et al. Comparison of)]TJ
2.175 -1.25 Td
(rofecoxib, celecoxib, and naproxen on renal function in elderly)Tj
T*
[(subjects receiving a normal-salt diet. Clin Pharmacol )17.7 (Ther)]TJ
0 Tc 0 Tw T*
(2002;72:50-61.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Bombardier C, Laine L, Reicin )54.8 (A, et al. )17.7 (The )17.7 (VIGOR Study Group.)]TJ
2.175 -1.25 Td
(Comparison of upper gastrointestinal toxicity of rofecoxib and)Tj
T*
[(naproxen in patients with rheumatoid arthritis. )17.7 (VIGOR Study)]TJ
0 Tc T*
(Group. N Engl J Med 2000;343:1520-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875.1 (W)79.9 (eir MR, Sperling RS, Reicin )54.8 (A, Gertz BJ. Selective COX-2)]TJ
2.175 -1.25 Td
[(inhibition and cardiovascular ef)17.7 (fects: a review of the rofecoxib)]TJ
T*
[(development program [review]. )54.8 (Am Heart J 2003;146:591-604.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (Senthilselvan )54.8 (A. Prevalence of physician-diagnosed asthma in)]TJ
0 Tc 2.175 -1.25 Td
[(Saskatchewan, 1981 to 1990. Chest 1998;1)36.9 (14:388-92.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
-0.00011 Tc 8 0 0 8 54.5 35.9844 Tm
(Pope: Editorial)Tj
0 Tc 0 Tw 60.9375 -0.0313 Td
(1037)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
119.868 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
14 0 obj
<>stream
8;Z\7$a.?#%*ST&R-Ql>erDOi$>9V5'_C)1b]V\t'CLRkYJL(im.`E5JD7jOF*oc)
7id.4(fZ=0N=>%R%_b$%/hAtEIrej/gB43
i01jo?'\WQQA+U<=f;42Eh8N%p`,R*)nA[2`Q%DR'sK5eks[Yd+AKA:ehWGe`ml]o
`.*\o-o]iD=*ffgQaQ5WJ/7Uk$>bFLbh2m\0PNmHL[:@^hCjikIrq7mR#`+mL\!V0
kaAfoR4,;dDdI?HkIR,F`r^\e"F2mqDMiG&ha'0:nF6:_X?rUW-km#B6D74(>QfBo
Q]Na8YKH8[mG7fHqdfYDr!`X*,hNb~>
endstream
endobj
18 0 obj
[/Indexed/DeviceRGB 255 17 0 R]
endobj
17 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
87 0 obj
<>
endobj
39 0 obj
<>
endobj
50 0 obj
<>
endobj
37 0 obj
<>
endobj
80 0 obj
<>
endobj
99 0 obj
<>
endobj
40 0 obj
<>
endobj
63 0 obj
<>stream
HU{PSg7\S^עAruѺkEDvAk@p)H(H BH@^ @E|>Yvζl=7F?;͜;3q{U#Ŋ3EW c}qv#ط]&$q'\XT>Q#]Y&[GOq+%J8-][f߿*婒E2&2kD-&E<#y1RL$uf_ẅeL2#&2&J%+ELrV;q2EL*NEoԾ|w°)̃86<a8"a+0l[; DZP01#?bx~Oh;BxO(wy&Mꟼ`?p2eٔGX=8W3No.M5=3|A/6l?\1٪6WhE[ne
ԅzР\/_ב 3H3%q -*vnWX%B/9mv8|%zhjo77ɞ;,T7h>h2}af5G^d[lpj^